Chinese pharmaceuticals company Beijing Kexing Bioproducts said on Tuesday that preliminary tests on its A/H1N1 influenza vaccines have proven the drug "safe and reliable" on humans.
"On Tuesday, none of the volunteers participating in our clinical tests exhibited any signs of severe, adverse drug reactions, during a three-day safety observation period," said Yin Weidong, general manager of Beijing Kexing Bioproducts, also known as the Sinovac Biotech Ltd.
Initial tests showed the company's product was safe and reliable, Yin said, adding that the company would publish a preliminary report on the vaccine in early August.
Slightly more than 1,600 volunteers from Beijing took part in the trials and were vaccinated in turns from July 22 to July 25.
The tests aim to specify dosage amounts of the vaccines.
A previous report said the tests would last for about two months until mid September. Participants between 3 and 60 would receive a second round of vaccination 21 days after their initial inoculation. Those aged over 60 would only receive one round.
(Xinhua News Agency July 28, 2009)
